Federman identified an antigen associated with osteosarcoma cell surface (ALCAM) and alpha-AL-HPLN, a tailored anti-ALCAM-hybrid polymerized liposomal nanoparticle immune conjugate (Butoescu et al., 2009). Here, ALCAM is linked to osteosarcoma.